13F-HR filed by ACUTA CAPITAL PARTNERS, LLC
ACUTA CAPITAL PARTNERS, LLC filed this 13F-HR for the quarter ended 2026-06-30, filed 2026-08-14, with 23 holding rows worth $143,494,671.
- Accession
- 0001104659-26-096822
- Filer
- CIK 1582844
- Filed
- 2026-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2026
A holdings report, 23 entries on the cover page, a total value of $143,494,671 stated on the cover page (in dollars after the unit check, H1), rows summing to $143,494,671 with VALUE read as dollars as filed, 13F file number 028-16527. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES I | 74006W207 | COM NEW | 82,796 | $27,719,273 | dollars as filed | |
| WHITEHAWK THERAPEUTICS INC | 00032Q104 | CMN | 4,685,912 | $21,461,477 | dollars as filed | |
| TANGO THERAPEUTICS INC | 87583X109 | COM | 390,949 | $12,221,066 | dollars as filed | |
| SUTRO BIOPHARMA INC | 869367201 | COMMON STOCK | 270,251 | $8,972,333 | dollars as filed | |
| ARRIVENT BIOPHARMA INC | 04272N102 | COM | 218,694 | $7,597,430 | dollars as filed | |
| 4D MOLECULAR THERAPEUTICS INC COM | 35104E100 | Stock | 507,801 | $6,753,753 | dollars as filed | |
| BRIGHT MINDS BIOSCIENCES INC | 10919W405 | COMMON STOCK | 92,745 | $6,510,699 | dollars as filed | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 532,481 | $5,228,963 | dollars as filed | |
| ERASCA INC COM | 29479A108 | Stock | 265,199 | $4,858,446 | dollars as filed | |
| SURROZEN INC | 86889P208 | COMMON STOCK | 173,395 | $4,499,600 | dollars as filed | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 4,705 | $4,365,158 | dollars as filed | |
| MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD | 61559X104 | Stock | 215,652 | $4,198,744 | dollars as filed | |
| DESIGN THERAPEUTICS INC | 25056L103 | COM | 282,564 | $4,088,701 | dollars as filed | |
| MINERVA NEUROSCIENCES INC | 603380205 | COM NEW | 709,500 | $3,937,725 | dollars as filed | |
| TAYSHA GENE THERAPIES INC | 877619106 | COMMON STOCK | 561,808 | $3,825,912 | dollars as filed | |
| AVALYN PHARMA INC | 05348Y105 | COMMON STOCK | 115,000 | $3,785,800 | dollars as filed | |
| AVALO THERAPEUTICS INC | 05338F306 | COMMON STOCK | 186,308 | $3,442,972 | dollars as filed | |
| AMYLYX PHARMACEUTICALS INC | 03237H101 | COM | 168,115 | $3,019,345 | dollars as filed | |
| ARTIVA BIOTHERAPEUTICS INC | 04317A107 | COM | 260,416 | $2,526,035 | dollars as filed | |
| COMPASS THERAPEUTICS INC | 20454B104 | COM | 595,213 | $1,303,516 | dollars as filed | |
| UNITED THERAPEUTICS CORP DEL COM | 91307C102 | Stock | 2,224 | $1,205,030 | dollars as filed | |
| CONTINEUM THERAPEUTICS INC CL A | 21217B100 | Stock | 63,095 | $1,034,127 | dollars as filed | |
| LB PHARMACEUTICALS INC | 50180M108 | COMMON STOCK | 28,919 | $938,566 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-26-096822 | this filing | 2026-08-14 | acceptance time not in the bulk data set |